Skip to content

Study · Non-randomized trial · n = 2,760 · 2017

6 results

Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials.

Blonde L, Chava P, Dex T, Lin J, Nikonova EV, Goldenberg RM

Diabetes, obesity & metabolism29 Nov 2016Cited by 17 (Europe PMC)

PMID27767249 (opens in a new tab)PMCIDPMC5299604 (opens in a new tab)DOI10.1111/dom.12815 (opens in a new tab)PepBankPUB-27767249
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes receiving oral drugs, lixisenatide reduced HbA1c significantly more than placebo.

    In plain wordsLixisenatide reduced long-term blood sugar more than placebo in patients receiving background oral diabetes drugs.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c reduction, oral-drug background
    Study

    n = 2,760

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with placebo, LIXI treatment led to significantly greater reductions in glycated haemoglobin (HbA1c),
    2 context sentences
    Summary · context
    Patients were divided into baseline therapy groups: those receiving oral antidiabetes drugs (OADs) at baseline (n = 2760) or those receiving basal insulin at baseline (n = 1198).
    Summary · context
    This study was a pooled analysis of patient-level data from the LIXI GetGoal studies comparing LIXI and placebo.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients receiving oral diabetes drugs, lixisenatide increased composite HbA1c target attainment without symptomatic hypoglycaemia or weight gain versus placebo.

    In plain wordsWith oral diabetes drugs, lixisenatide increased target blood sugar attainment without symptomatic low blood sugar or weight gain compared with placebo.

    Peptide
    Lixisenatide
    Outcome
    IncreaseComposite glycemic target without symptomatic hypoglycaemia or weight gain, oral-drug background
    Study

    n = 2,760

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Composite endpoint attainment
    34%
    lixisenatide, OAD
    Composite endpoint attainment
    18%
    placebo, OAD
    P value
    < 0.0001
    OAD

    Source sentences

    Summary
    and greater achievement of the composite endpoint of HbA1c <7.0% (53 mmol/mol) with no symptomatic hypoglycaemia and no weight gain in either the OAD (34% vs 18%; P < .0001) or the basal insulin groups (19% vs 10%; P < .0001).
    1 context sentence
    Summary · context
    This study was a pooled analysis of patient-level data from the LIXI GetGoal studies comparing LIXI and placebo.
  3. 03HumanNon-randomized trialSafety outcome

    In patients receiving oral diabetes drugs, symptomatic hypoglycaemia was more frequent with lixisenatide than placebo.

    In plain wordsSymptomatic low blood sugar was more frequent with lixisenatide than placebo in patients receiving oral diabetes drugs.

    Peptide
    Lixisenatide
    Outcome
    IncreaseSymptomatic hypoglycaemia, oral-drug background
    Study

    n = 2,760

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Symptomatic hypoglycaemia
    5%
    lixisenatide, OAD
    Symptomatic hypoglycaemia
    3%
    placebo, OAD
    P value
    0.0098
    OAD

    Source sentences

    Summary
    Treatment with LIXI was associated with a greater percentage of patients experiencing a symptomatic hypoglycaemic event compared with placebo in both the OAD (5% vs 3%; P = .0098) and basal insulin groups (27% vs 17%; P < .0001).
    1 context sentence
    Summary · context
    This study was a pooled analysis of patient-level data from the LIXI GetGoal studies comparing LIXI and placebo.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes receiving basal insulin, lixisenatide reduced HbA1c significantly more than placebo.

    In plain wordsLixisenatide reduced long-term blood sugar more than placebo in patients receiving background basal insulin.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c reduction, basal-insulin background
    Study

    n = 1,198

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with placebo, LIXI treatment led to significantly greater reductions in glycated haemoglobin (HbA1c),
    2 context sentences
    Summary · context
    Patients were divided into baseline therapy groups: those receiving oral antidiabetes drugs (OADs) at baseline (n = 2760) or those receiving basal insulin at baseline (n = 1198).
    Summary · context
    This study was a pooled analysis of patient-level data from the LIXI GetGoal studies comparing LIXI and placebo.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients receiving basal insulin, lixisenatide increased composite HbA1c target attainment without symptomatic hypoglycaemia or weight gain versus placebo.

    In plain wordsWith basal insulin, lixisenatide increased target blood sugar attainment without symptomatic low blood sugar or weight gain compared with placebo.

    Peptide
    Lixisenatide
    Outcome
    IncreaseComposite glycemic target without symptomatic hypoglycaemia or weight gain, basal-insulin background
    Study

    n = 1,198

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Composite endpoint attainment
    19%
    lixisenatide, basal insulin
    Composite endpoint attainment
    10%
    placebo, basal insulin
    P value
    < 0.0001
    basal insulin

    Source sentences

    Summary
    and greater achievement of the composite endpoint of HbA1c <7.0% (53 mmol/mol) with no symptomatic hypoglycaemia and no weight gain in either the OAD (34% vs 18%; P < .0001) or the basal insulin groups (19% vs 10%; P < .0001).
    1 context sentence
    Summary · context
    This study was a pooled analysis of patient-level data from the LIXI GetGoal studies comparing LIXI and placebo.
  6. 06HumanNon-randomized trialSafety outcome

    In patients receiving basal insulin, symptomatic hypoglycaemia was more frequent with lixisenatide than placebo.

    In plain wordsSymptomatic low blood sugar was more frequent with lixisenatide than placebo in patients receiving basal insulin.

    Peptide
    Lixisenatide
    Outcome
    IncreaseSymptomatic hypoglycaemia, basal-insulin background
    Study

    n = 1,198

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Symptomatic hypoglycaemia
    27%
    lixisenatide, basal insulin
    Symptomatic hypoglycaemia
    17%
    placebo, basal insulin
    P value
    < 0.0001
    basal insulin

    Source sentences

    Summary
    Treatment with LIXI was associated with a greater percentage of patients experiencing a symptomatic hypoglycaemic event compared with placebo in both the OAD (5% vs 3%; P = .0098) and basal insulin groups (27% vs 17%; P < .0001).
    1 context sentence
    Summary · context
    This study was a pooled analysis of patient-level data from the LIXI GetGoal studies comparing LIXI and placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.